Literature DB >> 23960727

Cataract associated with high-dose hematopoietic colony stimulating factor, case report and literature review.

Soad K Aljaouni1, Hanadi M Aljedani.   

Abstract

Granulocyte-colony stimulating factor (G-CSF) is a lineage-restricted hematopoietic growth factor. It induces proliferation and maturation of neutrophilic precursors and progenitors and activates neutrophil functions. It is used to ameliorate or prevent profound neutropenia and its consequences. G-CSF therapy in neutropenic disorders increases neutrophil count and improves infectious complications. However, it is not without side effects. Here, we discuss the case of a 2 years old patient with Kostmann's disease who developed cataracts following high-dose G-CSF therapy. We also review the relevant literature on G-CSF-related complications.

Entities:  

Keywords:  Cataract; Congenital neutropenia; G-CSF; Kostmann’s disease; Side effects of G-CSF therapy

Year:  2010        PMID: 23960727      PMCID: PMC3730976          DOI: 10.1016/j.jsps.2010.02.008

Source DB:  PubMed          Journal:  Saudi Pharm J        ISSN: 1319-0164            Impact factor:   4.330


  29 in total

1.  Guidelines on the use of colony-stimulating factors in haematological malignancies.

Authors:  Antonio Pagliuca; Patrick A Carrington; Ruth Pettengell; Simoon Tule; Jane Keidan
Journal:  Br J Haematol       Date:  2003-10       Impact factor: 6.998

2.  Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy.

Authors:  J R Deayton; P Wilson; C A Sabin; C C Davey; M A Johnson; V C Emery; P D Griffiths
Journal:  AIDS       Date:  2000-06-16       Impact factor: 4.177

3.  Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy.

Authors:  M H Freedman; M A Bonilla; C Fier; A A Bolyard; D Scarlata; L A Boxer; S Brown; B Cham; G Kannourakis; S E Kinsey; P G Mori; T Cottle; K Welte; D C Dale
Journal:  Blood       Date:  2000-07-15       Impact factor: 22.113

4.  Long-term follow-up of granulocyte colony-stimulating factor receptor mutations in patients with severe congenital neutropenia: implications for leukaemogenesis and therapy.

Authors:  Phil J Ancliff; Rosemary E Gale; Ri Liesner; Ian Hann; David C Linch
Journal:  Br J Haematol       Date:  2003-02       Impact factor: 6.998

5.  Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy.

Authors:  V Trillet-Lenoir; J Green; C Manegold; J Von Pawel; U Gatzemeier; B Lebeau; A Depierre; P Johnson; G Decoster; D Tomita
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

6.  Frequency of point mutations in the gene for the G-CSF receptor in patients with chronic neutropenia undergoing G-CSF therapy.

Authors:  N Tidow; C Pilz; B Kasper; K Welte
Journal:  Stem Cells       Date:  1997       Impact factor: 6.277

Review 7.  Late effects of total body irradiation.

Authors:  A Barrett; J Nicholls; B Gibson
Journal:  Radiother Oncol       Date:  1987-06       Impact factor: 6.280

8.  The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy.

Authors:  Philip S Rosenberg; Blanche P Alter; Audrey A Bolyard; Mary Ann Bonilla; Laurence A Boxer; Bonnie Cham; Carol Fier; Melvin Freedman; George Kannourakis; Sally Kinsey; Beate Schwinzer; Connie Zeidler; Karl Welte; David C Dale
Journal:  Blood       Date:  2006-02-23       Impact factor: 22.113

9.  Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: a EuroSIDA study, 1994-2001.

Authors:  I Yust; Z Fox; M Burke; A Johnson; D Turner; A Mocroft; C Katlama; B Ledergerber; P Reiss; O Kirk
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-06-30       Impact factor: 3.267

10.  Transgenic mice expressing a hemopoietic growth factor gene (GM-CSF) develop accumulations of macrophages, blindness, and a fatal syndrome of tissue damage.

Authors:  R A Lang; D Metcalf; R A Cuthbertson; I Lyons; E Stanley; A Kelso; G Kannourakis; D J Williamson; G K Klintworth; T J Gonda
Journal:  Cell       Date:  1987-11-20       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.